Advertisement

Drudge Retort: The Other Side of the News
Monday, October 11, 2021

:Merck Press Release: Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that Merck has submitted an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for molnupiravir, an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in adults who are at risk for progressing to severe COVID-19 and/or hospitalization. The companies are actively working with regulatory agencies worldwide to submit applications for emergency use or marketing authorization in the coming months. The submission is based on positive results from a planned interim analysis from the Phase 3 MOVe-OUT clinical trial, which evaluated molnupiravir in non-hospitalized adult patients with mild-to-moderate COVID-19 who were at risk for progressing to severe COVID-19 and/or hospitalization. At the interim analysis, molnupiravir reduced the risk of hospitalization or death by approximately 50%; 7.3% of patients who received molnupiravir were either hospitalized or died through Day 29 following randomization (28/385), compared with 14.1% of placebo-treated patients (53/377); p=0.0012. Through Day 29, no deaths were reported in patients who received molnupiravir, as compared to 8 deaths in patients who received placebo. The incidence of any adverse event was comparable in the molnupiravir and placebo groups (35% and 40%, respectively). The incidence of drug-related adverse events was also comparable (12% and 11%, respectively), and fewer subjects in the molnupiravir group discontinued therapy due to an adverse event compared to the placebo group (1.3% and 3.4%, respectively).

More

Comments

Admin's note: Participants in this discussion must follow the site's moderation policy. Profanity will be filtered. Abusive conduct is not allowed.

This looks good but why stop an ongoing trial?

#1 | Posted by Tor at 2021-10-11 04:33 PM | Reply

#1 It's only chemical analog is Invermectin. Trump took it. No patent. Cured half of India for $2.95.

Sort of like how Aspartane only has one chemical analogue - neurotoxin pesticides.

#2 | Posted by HeliumRat at 2021-10-11 05:04 PM | Reply | Funny: 1

But is this dope endorsed by Mr. Ed, Secretariat and the Budweiser Clydesdales?
-Millions hypnotized by a dancing orange fascist

#3 | Posted by catdog at 2021-10-11 05:07 PM | Reply

Assuming these pills work those who qualify for them should be required to take them on site and their needing the pills be a matter of public record.

I don't want any science deniers surviving because of lying.

#4 | Posted by Tor at 2021-10-11 05:22 PM | Reply

#2 | Posted by HeliumRat

Link(s)?

#5 | Posted by GalaxiePete at 2021-10-11 07:51 PM | Reply

#5

Link?

Be careful what you ask for.

#6 | Posted by madbomber at 2021-10-11 08:02 PM | Reply

"forces the SARS-CoV-2 coronavirus to mutate itself to death"

People will take that but they won't take a vaccine that (according to them, falsely) mutates their own DNA?

#7 | Posted by snoofy at 2021-10-11 08:04 PM | Reply

"The interim efficacy data on the drug, developed with Ridgeback Biotherapeutics..."

So who have they been giving campaign contributions to??

Is this a stock that Bo-tox Pelosi or the Kentucky Turtle invested in this company? IF SO, I'm buying stock tomorrow.

#8 | Posted by jamesgelliott at 2021-10-11 09:17 PM | Reply

Nature's Twitter account is FIRE!

#9 | Posted by snoofy at 2021-10-11 09:24 PM | Reply

No serious loyal Trumkp supporter will get vaccinated and now they will have more science to refuse to take. They reject prevention of the Virus and now they will reject cures for the Virus because it proves how loyal cult members are.

#10 | Posted by danni at 2021-10-12 03:44 PM | Reply

Comments are closed for this entry.

Home | Breaking News | Comments | User Blogs | Stats | Back Page | RSS Feed | RSS Spec | DMCA Compliance | Privacy | Copyright 2021 World Readable

Drudge Retort